{"title":"合成林可酰胺类药物伊博霉素和链霉素对携带erm基因的眼部耐多药甲氧西林金黄色葡萄球菌有活性。","authors":"","doi":"10.1016/j.jgar.2024.09.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Antimicrobial resistance is a global pandemic that poses a major threat to vision health as ocular bacteria, especially methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), are becoming increasingly resistant to first-line therapies. Here we evaluated the antimicrobial activity of new synthetic lincosamides in comparison to currently used antibiotics against clinical ocular MRSA isolates.</div></div><div><h3>Methods</h3><div>Antimicrobial susceptibility testing was performed by broth microdilution for two novel synthetic lincosamides (iboxamycin and cresomycin) and eight comparator antibiotics against a collection of 50 genomically characterised ocular MRSA isolates, including isolates harbouring <em>erm</em> genes (<em>n</em> = 25).</div></div><div><h3>Results</h3><div>Both drugs were active against widespread MRSA clonal complexes CC8 and CC5. The MIC<sub>50</sub> and MIC<sub>90</sub> of iboxamycin were 0.06 and 2 mg/L, respectively. Cresomycin (MIC<sub>50</sub> = 0.06 mg/L) also displayed good activity with an <em>in vitro</em> potency four-fold higher (MIC<sub>90</sub> = 0.5 mg/L) than iboxamycin. In isolates harbouring <em>erm</em> genes, MIC<sub>90</sub> were >16, 2, and 0.5 mg/L for clindamycin, iboxamycin, and cresomycin, respectively. The <em>in vitro</em> potencies of iboxamycin and cresomycin were similar or higher than that of comparator agents and were not impacted by multidrug-resistance phenotypes or by the presence of <em>erm</em> genes when compared with clindamycin.</div></div><div><h3>Conclusions</h3><div>Our results demonstrate that iboxamycin and cresomycin display potent <em>in vitro</em> activity against ocular MRSA isolates, including multidrug-resistant isolates harbouring <em>erm</em> genes.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthetic lincosamides iboxamycin and cresomycin are active against ocular multidrug-resistant methicillin-resistant Staphylococcus aureus carrying erm genes\",\"authors\":\"\",\"doi\":\"10.1016/j.jgar.2024.09.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Antimicrobial resistance is a global pandemic that poses a major threat to vision health as ocular bacteria, especially methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), are becoming increasingly resistant to first-line therapies. Here we evaluated the antimicrobial activity of new synthetic lincosamides in comparison to currently used antibiotics against clinical ocular MRSA isolates.</div></div><div><h3>Methods</h3><div>Antimicrobial susceptibility testing was performed by broth microdilution for two novel synthetic lincosamides (iboxamycin and cresomycin) and eight comparator antibiotics against a collection of 50 genomically characterised ocular MRSA isolates, including isolates harbouring <em>erm</em> genes (<em>n</em> = 25).</div></div><div><h3>Results</h3><div>Both drugs were active against widespread MRSA clonal complexes CC8 and CC5. The MIC<sub>50</sub> and MIC<sub>90</sub> of iboxamycin were 0.06 and 2 mg/L, respectively. Cresomycin (MIC<sub>50</sub> = 0.06 mg/L) also displayed good activity with an <em>in vitro</em> potency four-fold higher (MIC<sub>90</sub> = 0.5 mg/L) than iboxamycin. In isolates harbouring <em>erm</em> genes, MIC<sub>90</sub> were >16, 2, and 0.5 mg/L for clindamycin, iboxamycin, and cresomycin, respectively. The <em>in vitro</em> potencies of iboxamycin and cresomycin were similar or higher than that of comparator agents and were not impacted by multidrug-resistance phenotypes or by the presence of <em>erm</em> genes when compared with clindamycin.</div></div><div><h3>Conclusions</h3><div>Our results demonstrate that iboxamycin and cresomycin display potent <em>in vitro</em> activity against ocular MRSA isolates, including multidrug-resistant isolates harbouring <em>erm</em> genes.</div></div>\",\"PeriodicalId\":15936,\"journal\":{\"name\":\"Journal of global antimicrobial resistance\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of global antimicrobial resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213716524001711\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global antimicrobial resistance","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213716524001711","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Synthetic lincosamides iboxamycin and cresomycin are active against ocular multidrug-resistant methicillin-resistant Staphylococcus aureus carrying erm genes
Objective
Antimicrobial resistance is a global pandemic that poses a major threat to vision health as ocular bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA), are becoming increasingly resistant to first-line therapies. Here we evaluated the antimicrobial activity of new synthetic lincosamides in comparison to currently used antibiotics against clinical ocular MRSA isolates.
Methods
Antimicrobial susceptibility testing was performed by broth microdilution for two novel synthetic lincosamides (iboxamycin and cresomycin) and eight comparator antibiotics against a collection of 50 genomically characterised ocular MRSA isolates, including isolates harbouring erm genes (n = 25).
Results
Both drugs were active against widespread MRSA clonal complexes CC8 and CC5. The MIC50 and MIC90 of iboxamycin were 0.06 and 2 mg/L, respectively. Cresomycin (MIC50 = 0.06 mg/L) also displayed good activity with an in vitro potency four-fold higher (MIC90 = 0.5 mg/L) than iboxamycin. In isolates harbouring erm genes, MIC90 were >16, 2, and 0.5 mg/L for clindamycin, iboxamycin, and cresomycin, respectively. The in vitro potencies of iboxamycin and cresomycin were similar or higher than that of comparator agents and were not impacted by multidrug-resistance phenotypes or by the presence of erm genes when compared with clindamycin.
Conclusions
Our results demonstrate that iboxamycin and cresomycin display potent in vitro activity against ocular MRSA isolates, including multidrug-resistant isolates harbouring erm genes.
期刊介绍:
The Journal of Global Antimicrobial Resistance (JGAR) is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes.
JGAR is a dedicated journal for all professionals working in research, health care, the environment and animal infection control, aiming to track the resistance threat worldwide and provides a single voice devoted to antimicrobial resistance (AMR).
Featuring peer-reviewed and up to date research articles, reviews, short notes and hot topics JGAR covers the key topics related to antibacterial, antiviral, antifungal and antiparasitic resistance.